RT Journal Article
T1 COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
A1 Scarfo, Lydia
A1 Chatzikonstantinou, Thomas
A1 Rigolin, Gian Matteo
A1 Quaresmini, Giulia
A1 Motta, Marina
A1 Vitale, Candida
A1 Garcia-Marco, Jose Antonio
A1 Hernandez-Rivas, Jose Angel
A1 Miras, Fatima
A1 Baile, Monica
A1 Marquet, Juan
A1 Niemann, Carsten U
A1 Reda, Gianluigi
A1 Munir, Talha
A1 Gimeno, Eva
A1 Marchetti, Monia
A1 Quaglia, Francesca Maria
A1 Varettoni, Marzia
A1 Delgado, Julio
A1 Iyengar, Sunil
A1 Janssens, Ann
A1 Marasca, Roberto
A1 Ferrari, Angela
A1 Cuellar-Garcia, Carolina
A1 Itchaki, Gilad
A1 Špaček, Martin
A1 De Paoli, Lorenzo
A1 Laurenti, Luca
A1 Levin, Mark-David
A1 Lista, Enrico
A1 Mauro, Francesca R
A1 Šimkovič, Martin
A1 Van Der Spek, Ellen
A1 Vandenberghe, Elisabeth
A1 Trentin, Livio
A1 Wasik-Szczepanek, Ewa
A1 Ruchlemer, Rosa
A1 Bron, Dominique
A1 De Paolis, Maria Rosaria
A1 Del Poeta, Giovanni
A1 Farina, Lucia
A1 Foglietta, Myriam
A1 Gentile, Massimo
A1 Herishanu, Yair
A1 Herold, Tobias
A1 Jaksic, Ozren
A1 Kater, Arnon P
A1 Kersting, Sabina
A1 Malerba, Lara
A1 Orsucci, Lorella
A1 Popov, Viola Maria
A1 Sportoletti, Paolo
A1 Yassin, Mohamed
A1 Pocali, Barbara
A1 Barna, Gabor
A1 Chiarenza, Annalisa
A1 Dos-Santos, Gimena
A1 Nikitin, Eugene
A1 Andres, Martin
A1 Dimou, Maria
A1 Doubek, Michael
A1 Enrico, Alicia
A1 Hakobyan, Yervand
A1 Kalashnikova, Olga
A1 Ortiz-Pareja, Macarena
A1 Papaioannou, Maria
A1 Rossi, Davide
A1 Shah, Nimish
A1 Shrestha, Amit
A1 Stanca, Oana
A1 Stavroyianni, Niki
A1 Strugov, Vladimir
A1 Tam, Constantine
A1 Zdrenghea, Mihnea
A1 Coscia, Marta
A1 Stamatopoulos, Kostas
A1 Rossi, Giuseppe
A1 Rambaldi, Alessandro
A1 Montserrat, Emili
A1 Foa, Robin
A1 Cuneo, Antonio
A1 Ghia, Paolo
K1 Pyrimidines
K1 Retrospective Studies
K1 SARS-CoV-2
K1 Severity of Illness Index
K1 Surveys and Questionnaires
AB Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
PB Nature Publishing Group
YR 2020
FD 2020-07-09
LK http://hdl.handle.net/10668/15913
UL http://hdl.handle.net/10668/15913
LA en
NO Scarfò, L., Chatzikonstantinou, T., Rigolin, G. M., Quaresmini, G., Motta, M., Vitale, C., et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia, 34(9), 2354-2363. https://doi.org/10.1038/s41375-020-0959-x
DS RISalud
RD Apr 15, 2025